Rhumbline Advisers Oncorus, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.04 - $1.86 $20,316 - $36,335	-19,535 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.44 - $5.62 $3,824 - $14,926	-2,656 Reduced 11.97%	19,535 $35,000
Q4 2021 Feb 10, 2022	SELL	$5.03 - $11.63 $2,771 - $6,408	-551 Reduced 2.42%	22,191 $117,000
Q3 2021 Nov 12, 2021	BUY	$9.29 - $14.27 $8,825 - $13,556	950 Added 4.36%	22,742 $212,000
Q2 2021 Aug 05, 2021	BUY	$13.3 - $17.3 $289,833 - $377,001	21,792 New	21,792 $301,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.